Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Overview
Nutriband Inc is a Florida-based pharmaceutical company specializing in the development of transdermal drug delivery systems that incorporate advanced abuse-deterrent technologies. Its core business revolves around transdermal pharmaceutical products engineered to mitigate the risks of drug abuse, misuse, diversion, and accidental exposure, with a special emphasis on addressing the global opioid crisis. Utilizing proprietary technology that integrates aversive agents into transdermal patches, Nutriband is dedicated to improving patient safety while ensuring essential medications remain accessible for those in need.
Advanced Abuse-Deterrent Technology
The company’s flagship innovation, AVERSA technology, is designed to deter the oral abuse of potent drugs by utilizing taste aversion methods. This technology can be incorporated into various transdermal patches, a critical step toward preventing accidental exposures—particularly in vulnerable populations such as young children. The patented approach provides an additional safeguard by making the potential for abuse less appealing, thereby enhancing the overall safety profile of drugs with abuse potential.
Business Model and Operations
Nutriband Inc generates revenue primarily through the sale of consumer transdermal and coated products, as well as through contract manufacturing services provided by its wholly owned subsidiary, Pocono Pharma. The company leverages its strategic partnerships with top industry players to extend its market reach, including engagements with major retailers and established pharmaceutical manufacturing organizations. This diversified revenue approach not only supports the current portfolio but also positions Nutriband as a flexible partner in both the healthcare and contract manufacturing sectors.
Strategic Partnerships and Intellectual Property
A cornerstone of Nutriband’s success is its robust global intellectual property portfolio, which spans across more than 40 countries including the United States, Europe, Japan, and Australia. Such extensive protection underpins its innovative AVERSA technology and provides a competitive edge in the increasingly critical field of abuse-deterrent transdermal systems. Strategic alliances with industry experts such as Kindeva Drug Delivery further reinforce its position by ensuring that large-scale manufacturing processes align with FDA guidelines and international industry standards.
Market Position and Industry Significance
Operating at the nexus of pharmaceutical innovation and patient safety, Nutriband Inc is positioned distinctively in the competitive landscape of transdermal drug delivery systems. Its strategic focus on developing abuse-deterrent products addresses a significant unmet need in the market, particularly in the context of managing opioid-related risks without compromising therapeutic access. Through its commitment to evolving industry standards and enhancing product safety, Nutriband has established itself as a forward-thinking entity within a critical market segment.
Product Portfolio and Future Applications
While its lead product, an abuse-deterrent fentanyl patch, remains at the forefront of its development efforts, Nutriband is actively expanding its portfolio to include additional transdermal therapies. By integrating its core AVERSA technology across multiple product lines, the company aims to address a wide spectrum of medications with abuse potential, including opioids and stimulants. This strategy not only diversifies its technology applications but also solidifies its reputation as an innovator in transdermal pharmaceutical solutions.
Commitment to Safety and Regulatory Compliance
At the heart of Nutriband’s mission is a dedication to enhancing patient safety through rigorous research, development, and close adherence to regulatory standards. The company emphasizes clear, methodical approaches that streamline market entry while upholding the highest safety measures. This balance of innovation and compliance is critical in a market where the prevention of misuse and accidental exposure is of paramount concern.
Overall, Nutriband Inc exemplifies a strategic blend of innovative product development, methodical market expansion, and a steadfast commitment to patient safety. Its robust technology platform, significant IP portfolio, and established industry partnerships underscore its role as a key contributor to the evolution of abuse-deterrent pharmaceutical products.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) endorses the 2022 CDC guidelines on opioid prescribing, emphasizing the need for abuse deterrent technologies in pain management. The new guidelines allow greater opioid access for those with chronic pain while recognizing the challenges of the prior restrictions. Nutriband's AVERSA™ technology aims to mitigate abuse risks associated with transdermal opioids. The lead product, AVERSA™ Fentanyl, is projected to generate $80M - $200M in potential annual sales post-launch, enhancing safety for vulnerable patient groups.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has entered into an exclusive manufacturing agreement with Fleur Marché for CBD and Botanical Patches. Nutriband's subsidiary, Active Intelligence, will be the exclusive manufacturer for these products. Fleur Marché, founded in 2019, focuses on wellness patches aimed at simplifying health solutions for busy consumers. Products are available in retailers such as Bed Bath and Beyond and Nordstrom. This partnership is expected to highlight Nutriband's manufacturing capabilities using innovative technologies.
Nutriband Inc. (NASDAQ:NTRB) announced its subsidiary, 4P Therapeutics, completed a Phase 1b clinical study for Sorrento Therapeutics (NASDAQ:SRNE). Results will be presented at the American College of Rheumatology (ACR) Convergence 2022 on November 13, 2022, highlighting significant improvements in rheumatoid arthritis disease measures at 50% of the standard dose. The study emphasizes the potential of the Sofusa lymphatic delivery platform for treating autoimmune diseases and showcases 4P Therapeutics' capabilities in advancing drug delivery products.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has been invited to speak at the 2023 Transdermal and Microneedle Conference in London on January 23-24. CEO Gareth Sheridan will present on improving transdermal technologies to reduce the abuse potential of medications, referencing their AVERSA technology. Additionally, COO Dr. Alan Smith will participate in a panel discussion on microneedles as a drug delivery tool. Other notable participants include representatives from Merck, GSK, and Sanofi.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced progress in collaboration with Kindeva Drug Delivery for their AVERSA™ Fentanyl patch, an abuse-deterrent transdermal system. Recent studies confirm that Nutriband's aversive coating can be produced with standard manufacturing processes, crucial for product development. The product has a projected peak annual sales potential of $80M - $200M within five years post-launch. Nutriband aims to finalize product configuration and transfer technology to Kindeva's commercial facility in California.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has initiated the application process for a dual listing on Upstream, a digital trading app. This move aims to tap into a global investor base, facilitating trades in USDC digital currency and traditional payment methods. CEO Gareth Sheridan emphasized that this listing could enhance shareholder value and liquidity while expanding access to international markets. Approval from MERJ Exchange is pending; however, Nutriband's adherence to NASDAQ standards is sufficient for compliance. The company is known for developing abuse deterrent technologies for pharmaceuticals.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) will be featured on the RedChip Money Report airing on Bloomberg TV this Saturday, September 17, at 7 p.m. ET. The interview will highlight various aspects of the company, including expanded patents, commercialization plans, and Q2 revenue results. Chairman & President Serguei Melnik will discuss these developments, which could pique investor interest. Bloomberg TV reaches approximately 73 million homes across the U.S.
Nutriband Inc. (NASDAQ:NTRB) reported significant growth in its Q2 2022 financial results, achieving record quarterly revenue of $0.5 million, a 113% increase year-over-year. Over six months, revenue rose 44%. The company received a favorable court ruling enabling the cancellation of 1.2 million shares, representing 15% of outstanding shares at the time. Nutriband continues to expand its AVERSA™ intellectual property, now protected in 45 countries. However, net loss increased to $1.0 million from $0.5 million year-over-year.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the effective date of a 7:6 forward stock split that took place on August 12, 2022, with a record date of August 15, 2022. Each holder of 6 shares of common stock received 7 shares, with no change to the per-share par value. The stock split will not affect stockholders' equity percentages. Additionally, the exercise price of outstanding warrants will be adjusted to $6.43 per share, corresponding to the stock split ratio. Book-entry holders do not need to take action, while those seeking stock certificates will receive further instructions.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the receipt of a Notice of Allowance for its patent application from the Canadian Intellectual Property Office. This patent is crucial for the company's AVERSA™ transdermal abuse deterrent technology, enhancing intellectual property protection across North America.
The AVERSA™ technology aims to reduce drug misuse and abuse while ensuring accessibility for patients in need. The lead product, AVERSA™ Fentanyl, is projected to achieve peak annual sales of $80M - $200M. Nutriband's patent portfolio spans multiple countries, bolstering its market position.
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
What is Nutriband Inc's core business?
How does the AVERSA technology work?
What are the key revenue streams for Nutriband Inc?
How does Nutriband position itself within the pharmaceutical industry?
What strategic partnerships support Nutriband's operations?
In which markets are Nutriband's products available?
How is Nutriband addressing the opioid crisis?
How does Nutriband protect its innovative technology?
